Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Amgen (NQ: AMGN )

263.38 +2.19 (+0.84%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
48 49 Next >
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond
These five biotech companies could have a lot of room to run. 
Via The Motley Fool
Why Vera Therapeutics Stock Soared by 22% This Week
Executive changes and a bullish analyst take combined to boost sentiment on the company. 
Via The Motley Fool
Why NASDAQ:AMGN is a Top Pick for Dividend Investors.
Balancing Dividends and Fundamentals: The Case of AMGEN INC (NASDAQ:AMGN). 
Via Chartmill
Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance
Pharmaceutical companies, including Amgen Inc (NASDAQ: AMGN) and Pfizer Inc (NYSE: PFE), are strategically positioning themselves to tap into the  
Via Benzinga
AbbVie's Strategic Move: ImmunoGen Acquisition Triggers Golden Cross, Yet Valuation Caution Remains
AbbVie Inc (ABBV) stock is up 15% since acquiring ImmunoGen, but past Golden Cross rallies haven't sustained. With high valuation and competition, investors may want to wait for a pullback. 
Via Benzinga
How Is The Market Feeling About Amgen?
Via Benzinga
Looking At Amgen's Recent Unusual Options Activity
Via Benzinga
Investigating Amgen's Standing In Biotechnology Industry Compared To Competitors
Via Benzinga
Dogs of the Dow: January’s Top 3 Picks to Buy for Big Gains
Buying Dogs of the Dow stocks is an attractive strategy that involves buying stocks with high dividend yields that have often underperformed. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons
Via Investor Brand Network
GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons
EQNX::TICKER_START (NASDAQ:LEXX),(NASDAQ:AMGN),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:WW) EQNX::TICKER_END 
Via FinancialNewsMedia
Looking At Amgen's Recent Unusual Options Activity
Via Benzinga
Amgen Inc. (NASDAQ: AMGN) Records 52-Week High Tuesday Morning
Via Investor Brand Network
Amgen's Options: A Look at What the Big Money is Thinking
Via Benzinga
3 health care stocks off to strong starts in 2024
With the bullish news flow lately, the market has taken a liking to health care stocks in recent weeks - including these three early 2024 gainers. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Is AI More Valuable In Advertising Than Healthcare? Jim Cramer Questions Wall Street's Preference
Cramer shared his insights during his attendance at JPMorgan's healthcare conference, 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:AMGN),(NASDAQ:AMAM),(NASDAQ:ELEV),(NASDAQ:NKTX) EQNX::TICKER_END 
Via FinancialNewsMedia
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
From FN Media Group LLC
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting. 
Via Benzinga
A Rough Start To 2024 What Might Be In Store For The Rest Of 2024?
The market was weighed down by several negative factors that began before the bell even rang at Broad and Wall on the first trading day of this New Year. 
Via Talk Markets
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Will the Biotech sector sustain its momentum in 2024?
The iShares Biotechnology ETF (NASDAQ: IBB) emerged as a standout star, closing the first day of the year with a solid upswing of nearly 4%. 
Via MarketBeat
Topics ETFs
Revenge of the Boring Stocks! Dividends Are Sexy Again.
Dividend stocks are leading the way in the first few days of 2024, indicating that boring is back! What that means for investors now. 
Via InvestorPlace
Did Santa Claus Claus Leave Town A Day Early?
With the exception of the Dow, stocks are down hard to begin the new calendar year. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Dogs Of The Dow: Top 10 Highest Yielding Dow Jones Stocks, How To Get Dividends Of 3% to 7.4% In 2024
Twenty eight of the 30 Dow Jones Industrial Average components pay out dividends. A look at the top ten highest dividend yields. 
Via Benzinga
Topics Stocks
Exposures US Equities
3 Top ETFs I'm Planning to Buy Hand Over Fist in 2024, Despite All the Cheap Stocks on My Radar
I'm adding some ETFs to my retirement portfolio in 2024; here are the three I'm starting with. 
Via The Motley Fool
Topics ETFs Retirement
Exposures Pension
Amgen Stock Sees Relative Strength Rating Improve To 74
Amgen stock saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 69 to 74. 
Via Investor's Business Daily
There Are Only 5 Dow Stocks I Wouldn't Buy in 2024
There's a lot to like about Apple, Microsoft, and most of the Dow Jones Industrial Average components in 2024. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
48 49 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.